
Presentations
Documents
Body fat distribution, insulin resistance and NASH
Date added: | 08/05/2018 |
Date modified: | 08/05/2018 |
Filesize: | 8.89 MB |
Downloads: | 1370 |
Oral presentation given by CNR at the Meeting Quadrisocietario Diabesità (SICOB, SID, SIE, SIO), Pisa, Italy, 5th - 6th October 2017
Fatty liver disease is associated to increased glucogenic amino acids and decreased de novo...
Date added: | 08/05/2018 |
Date modified: | 08/05/2018 |
Filesize: | 256 Bytes |
Downloads: | 1263 |
"Fatty liver disease is associated to increased glucogenic amino acids and decreased de novo alanine synthesis"
Oral presentation given by CNR & UNITO at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD 2017), Lisbon, Portugal, 15th September 2017
P465L PPARγ mutation confers partial resistance to the hypolipidaemic action of fibrates
Date added: | 07/28/2018 |
Date modified: | 07/28/2018 |
Filesize: | 1.42 MB |
Downloads: | 974 |
Poster presentation given by UCAM at the Conference: “Metabolism in Action - Lifetime influence of genes and environment”, organized by the Copenhagen Bioscience Conferences, a Novo Nordisk Foundation initiative, Hillerød, Denmark, 1st - 5th October 2017
Development and Validation of the Collagen Neo-Epitope Biomarker Pro-C3 ‘FIB-C3 Score’ for Detection
Date added: | 07/28/2018 |
Date modified: | 07/28/2018 |
Filesize: | 256 Bytes |
Downloads: | 1310 |
"Development and Validation of the Collagen Neo-Epitope Biomarker Pro-C3 ‘FIB-C3 Score’ for Detection and Staging of Advanced Non-Alcoholic Fatty Liver Disease in a Large International Multi-Centre Patient Cohort"
Oral presentation given by UNEW, ICAN, UMC, UNITO & NB at the BASL Annual Meeting, Coventry, UK, 20th September 2017
Systems approaches to study obesity and metabolic co-morbidities
Date added: | 07/28/2018 |
Date modified: | 07/28/2018 |
Filesize: | 256 Bytes |
Downloads: | 1268 |
Oral presentation given by ORU at the 14th Key Symposium, Cambridge, UK, 20th September 2017
Metabolomics approaches to study NAFLD
Date added: | 06/02/2018 |
Date modified: | 06/02/2018 |
Filesize: | 256 Bytes |
Downloads: | 1413 |
Oral presentation given by ORU at the Federation of European Physiological Societies (FEPS) Congress, Vienna, Austria, 14th September 2017
NAFLD: Current & Future Therapeutic Approaches
Date added: | 06/02/2018 |
Date modified: | 06/02/2018 |
Filesize: | 256 Bytes |
Downloads: | 1430 |
Oral presentation given by UNEW at the BASL School of Hepatology, Newcastle upon Tyne, UK, 28th June 2017
How common is NASH in your diabetes clinic?
Date added: | 04/20/2018 |
Date modified: | 04/20/2018 |
Filesize: | 256 Bytes |
Downloads: | 1443 |
Oral presentation given by UNITO at the 1st International Conference on Fatty Liver (ICFL), Seville, Spain, 1st - 3rd June 2017
NASH Therapeutics: Targets Under Evaluation in Early Phase Trials
Date added: | 04/20/2018 |
Date modified: | 04/20/2018 |
Filesize: | 256 Bytes |
Downloads: | 1473 |
Oral presentation given by UNEW at the 1st International Conference on Fatty Liver (ICFL), Seville, Spain, 1st - 3rd June 2017
Why Should We Care About NAFLD?
Date added: | 04/20/2018 |
Date modified: | 04/20/2018 |
Filesize: | 256 Bytes |
Downloads: | 1470 |
Oral presentation given by UNEW at the 1st International Conference on Fatty Liver (ICFL), Seville, Spain, 1st - 3rd June 2017